Previous 10 | Next 10 |
BioMarin has 6 commercialised assets in the rare disease space, targeting e.g. lysosomal storage diseases. The company is on track for ~$1.8bn of revenues in FY21, and importantly, a small non-GAAP net income, reversing years of heavy losses. The company also has a PDUFA date on N...
Image source: The Motley Fool. BioMarin Pharmaceutical inc (NASDAQ: BMRN) Q3 2021 Earnings Call Oct 27, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: BioMarin Pharmaceutical inc (BMRN) Q3 2021 Earnings Call Transc...
BioMarin Pharmaceutical Inc. (BMRN) Q3 2021 Earnings Conference Call October 28, 2021, 4:30 PM ET Company Participants J.J. Bienaime – Chairman and Chief Executive Officer Traci Mc Carty – Vice President of Investor Relations Jeff Ajer – Executive Vice President and Chief...
BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates - Strong Commercial Launch of VOXZOGO™ for the Treatment of Children with Achondroplasia Ages 2 and Older Underway across Europe; U.S. Review Proceeding, Target Action Date Tracking to November ...
NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) in the United States District Court for the Northern D...
BioMarin to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, October 27 at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , Oct. 12, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bi...
Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...
BioMarin Hires Industry Veterans to Fill Key Roles in R&D and Technical Operations BioMarin Hires Industry Veterans to Fill Key Roles in R&D and Technical Operations Harold S. Bernstein, M.D., Ph.D. Named Senior Vice President, Chief Medical Officer and Head of Clini...
Evercore ISI has set up its list of key catalysts for the rest of 2021 in the biotechnology sector - including early-stage data readouts as well as some important legal and regulatory updates ahead for particular companies. Along the way it tees up its rule of thumb on biotech catalysts: "Alw...
The TransCon platform is designed to optimize the delivery of known drugs to target tissues. The valuation of Ascendis Pharma is largely a reflection of the potential of the platform rather than a sum of the parts figure based on the current pipeline assets. This $9.5 B market cap...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...